Investigator Name: Jeroen Hiltermann
Organization: University Medical Center Groningen, the Netherlands
Function: Principal Investigator
Role in GUIDE.MRD (brief description): Clinical lead within WP3 for lung cancer.
Expectation of GUIDE.MRD (brief description): Validation of ctDNA as a future tool in clinical practice
Telephone:+31652724086
E-mail address: t.j.n.hiltermann@umcg.nl
01 Universitaetsklinikum Hamburg-Eppendorf (UKE) – Germany
02 Aarhus Universitet (AU) – Denmark
03 Academisch Ziekenhuis Groningen (UMCG) – Netherlands
04 Centre Hospitalier Universitaire de Nice (CHUNICE) – France
05 Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncológicas Carlos III (FPS-CNIO) – Spain
06 LungenClinic Grosshansdorf GMBH (LUNGEN-CG) – Germany
07 Karolinska Institutet (KI) – Sweden
08 Illumina Cambridge Limited (ILLUMINA) – United Kingdom
09 Horizon Discovery Limited (HDL) – United Kingdom
10 LGC Clinical Diagnostics INC (LGC) – United States
11 The Synergist (SYNERGIST) – Belgium
12 Digestive Cancers Europe DICE (DiCE) – Belgium
13 Amgen (Europe) GMBH (AMGEN) – Switzerland
14 Bristol-Myers Squibb Company Corp (BMS) – United States
15 F. Hoffmann-La Roche AG (ROCHE) – Switzerland
16 Innovation Acta (INN-ACTA) – Italy
17 AstraZeneca UK Limited (AZ) – United Kingdom
18 Medizinische Universitat Graz (MUG) – Austria
19 Synergist Services (SYNERSERV) – Belgium
20 Asociatia Centrul Pentru Inovatie in Medicina (INOMED) – Romania
21 Centre Hospitalier Universitaire Montpellier (CHUM) – France
22 Aarhus Universitetshospital (AUH) – Denmark
23 Region Stockholm (KH) – Sweden
24 Lung Cancer Europe LUCE (LuCE) – Switzerland
25 AbbVie (AbbVie)
